Patent: 5,498,531
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 5,498,531
| Title: | Intron-mediated recombinant techniques and reagents |
| Abstract: | The present invention makes available methods and reagents for novel manipulation of nucleic acids. As described herein, the present invention makes use of the ability of intronic sequences, such as derived from group I, group II, or nuclear pre-mRNA introns, to mediate specific cleavage and ligation of discontinuous nucleic acid molecules. For example, novel genes and gene products can be generated by admixing nucleic acid constructs which comprise exon nucleic acid sequences flanked by intron sequences that can direct trans-splicing of the exon sequences to each other. The flanking intronic sequences can, by intermolecular complementation, form a reactive complex which promotes the transesterification reactions necessary to cause the ligation of discontinuous nucleic acid sequences to one another, and thereby generate a recombinant gene comprising the ligated exons. |
| Inventor(s): | Jarrell; Kevin A. (Arlington, MA) |
| Assignee: | President and Fellows of Harvard College (Cambridge, MA) |
| Application Number: | 08/119,512 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,498,531
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | See Plans and Pricing | 2039-02-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | See Plans and Pricing | 2039-02-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | See Plans and Pricing | 2039-02-26 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
